Valuation: Verastem, Inc.

Market Cap 674M 588M 555M 504M 944M 64.65B 948M 6.65B 2.56B 32.87B 2.53B 2.47B 106B P/E 2026 *
-4.55x
P/E 2027 * -6.39x
Enterprise Value 716M 624M 589M 535M 1B 68.67B 1.01B 7.06B 2.72B 34.91B 2.69B 2.63B 112B EV / Sales 2026 *
6.15x
EV / Sales 2027 * 3.72x
Free-Float
98.98%
Yield 2026 *
-
Yield 2027 * -
1 day-1.46%
1 week+1.64%
Current month+3.05%
1 month+9.09%
3 months+80.58%
6 months+34.54%
Current year-3.63%
1 week 7.2
Extreme 7.195
7.91
1 month 6.62
Extreme 6.62
8.54
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
10.82
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
39.6
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 2023-07-31
Director of Finance/CFO 39 2022-10-30
Chief Tech/Sci/R&D Officer - 2024-04-17
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 2023-07-31
Director/Board Member 69 2017-05-02
Date Insider Type Main position Quantity % Market Cap. Importance
8/3/26 Sell

Chief Executive Officer

-1,302 0.0021%
5/21/26 Free

Director

108,000 0.1229%
5/21/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
-1.46%+1.64%-17.79%-21.68% 674M
-0.31%+5.79%+47.13%+99.53% 70.88B
+0.39%+2.06%+39.38%+78.71% 62.49B
+5.46%+8.26%+32.73%+30.55% 26.34B
-3.21%-7.27%-17.10%+370.22% 26.21B
-2.64%-0.69%-0.17%-11.56% 24.13B
+0.71%+8.03%+25.03%-13.74% 20.72B
+2.12%-5.86%+161.58%+333.73% 15.36B
-0.22%+3.99%+45.54%+171.32% 14.46B
+0.73%+1.71%-5.51%+859.68% 14.24B
Average +0.18%+1.73%+31.08%+189.68% 27.55B
Weighted average by Cap. +0.21%+1.49%+35.50%+151.54%

Financials

2026 *2027 *
Net sales 116M 102M 95.88M 87.06M 163M 11.17B 164M 1.15B 443M 5.68B 437M 428M 18.28B 181M 158M 149M 135M 254M 17.38B 255M 1.79B 689M 8.84B 680M 665M 28.43B
Net income -166M -145M -137M -124M -232M -15.92B -233M -1.64B -631M -8.09B -623M -609M -26.04B -157M -137M -129M -117M -220M -15.07B -221M -1.55B -598M -7.66B -590M -577M -24.65B
Net Debt 41.9M 36.54M 34.5M 31.33M 58.7M 4.02B 58.94M 413M 159M 2.04B 157M 154M 6.58B -
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
26-09-18 US$7.440 -1.46% 4,497,074
26-09-17 US$7.550 +3.14% 1,734,248
26-09-16 US$7.320 -0.27% 1,452,334
26-09-15 US$7.340 -2.26% 2,840,151
26-09-14 US$7.510 +2.60% 1,514,530
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
7.440USD
Average target price
14.67USD
Spread / Average Target
+97.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!